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Abstract
Background: Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin generelated peptide (CGRP), is approved for migraine prevention in adults. Real-world data on the effectiveness of fremanezumab
are limited. This retrospective, observational cohort study assessed patient-reported migraine symptoms, health care resource
utilization (HCRU), and direct medical costs before and after fremanezumab treatment initiation.
Methods: Data were extracted from September 2018 through June 2020 from the Midwest component of EMRClaims+®, an
integrated health services database containing > 20 million medical records from national commercial insurance claims,
Medicare claims, and regional electronic medical records. Patients included in the cohort analysis were aged ≥ 18 years and
were administered fremanezumab, with enrollment or treatment history for ≥ 6 months prior (pre-index) to initiating
fremanezumab (index date) and ≥ 1 month after the index date (post-index), and without pregnancy or pregnancy-related
encounters during the study period. Patient-reported headache frequency, migraine pain intensity (MPI), composite migraine
symptoms, and HCRU were assessed pre-index and ≥ 1 month after fremanezumab initiation. Wilcoxon signed-rank tests
were used to compare means of migraine symptoms and outcomes and HCRU before and after fremanezumab initiation.
Results: Overall, 172 patients were eligible for analysis. Of patients who self-reported (n = 129), 83.7% reported improvement
in headache frequency or symptoms after fremanezumab treatment. Specifically, headache frequency decreased by 63%
after fremanezumab initiation: mean (standard deviation) headache frequency was 22.24 (9.29) days per month pre-index
versus 8.24 (7.42) days per month post-index (P < 0.0001). Mean MPI also decreased by 18% after fremanezumab initiation:
MPI was 5.47 (3.19) pre-index versus 4.51 (3.34) post-index (P = 0.014). Mean emergency room (ER) visits per month
decreased from 0.72 to 0.54 (P = 0.003), and mean outpatient visits per month decreased from 1.04 to 0.81 (P < 0.001). Mean
hospitalizations per month decreased, but the results did not reach statistical significance (P = 0.095). Hospitalization and ER
costs decreased, while outpatient costs increased, from pre-index to post-index, but differences were not statistically
significant (P ≥ 0.232).
Conclusions: Significant reductions in headache frequency, MPI, and HCRU were observed after fremanezumab initiation in
patients with migraine in a US real-world setting.
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Background
Migraine is a complex neurologic disease that affects
> 1 billion individuals worldwide, including 68.5 million in
the United States and 80 million in Western Europe [1]. Individuals with migraine experience headache attacks lasting 4
to 72 h that are accompanied by a range of symptoms, which
may include pulsing or throbbing headache pain, nausea,
vomiting, photophobia, phonophobia, blurred vision, and
aura [2, 3]. Experience of these symptoms commonly cooccurs with severe negative impact on daily activities and
quality of life [1, 4], so much so that migraine is the second
leading cause of years lived with disability worldwide [5]. In
the United States, current disability-adjusted life-years for migraine are 2.4 million (95% uncertainty interval, 1.53–3.44
[1]). Additionally, health care resource utilization (HCRU),
including primary health care visits, outpatient visits, and
emergency room (ER) visits, is higher among patients with
migraine compared to the general population [4]. Research
demonstrates that HCRU is reduced among patients who experience more headache-free days [6]. Thus, migraine prevention is typically recommended in patients with attacks
occurring ≥ 4 days per month to mitigate symptoms and associated disability [7, 8].
Fremanezumab is a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin generelated peptide (CGRP), a neuropeptide implicated in
the pathophysiology of migraine [9, 10]. Fremanezumab
has demonstrated efficacy, safety, and tolerability in
adults with episodic migraine (EM; headache occurring
< 15 days per month [11]) or chronic migraine (CM; ≥
15 headache days per month, with attacks meeting migraine criteria ≥ 8 days per month over 3 months’ time
[11]) in clinical trials [12, 13].
There are limited real-world effectiveness data for fremanezumab due to the recency (i.e., 2018) of its approval as a therapeutic indicated for migraine prevention
in adults. Real-world effectiveness data are critical as
they demonstrate the effects of a therapeutic when used
under less structured conditions compared to clinical
trials, including a broader patient population.
The lack of real-world data for fremanezumab is driven by
the fact that (1) patient measures assessing information such
as frequency of migraine attacks are not routinely captured,
and (2) insurance claims or hospital encounter data are not
appropriate data sources given the lack of structured symptom data. Quantifiable endpoints from real-world data are
needed to provide evidence for fremanezumab’s effectiveness
in less controlled, nonclinical trial conditions, which are considered in the development of coverage and utilization

management policy. Thus, this retrospective, observational
cohort study assessed patient-reported migraine symptoms
and HCRU before and after fremanezumab treatment
initiation.

Methods
Data source

Data were extracted from September 2018 through June
2020 from the Midwest component of EMRClaims+®, an integrated health services database containing > 20 million
medical records from national commercial insurance claims,
Medicare claims, and regional electronic medical records
(EMR) collected from 1988 to the present, with over 3.1 million facility encounters added annually. Additionally, this
database includes administrative insurance claims for approximately 690,000 individuals linked to an overlapping
health care provider database of EMR data, including laboratory values and provider billing files. Standard longitudinal
claims data, including pharmacy data and medical claims, are
available for managed care members who have medical encounters within the EMR-reporting hospitals and outpatient
facilities. Database elements are available as recently as 30
days from the time of extract, and EMR extracts are available
as recently as the last 2 weeks from extract. Insured parties
linked with the EMR are tracked through provider-aligned
patient panels, managed care membership, and a Master Patient Index.
Selection criteria for patient population

Patients were included in this cohort analysis if they were
aged ≥ 18 years and administered fremanezumab, with enrollment or treatment history for ≥ 6 months prior (i.e., preindex) to initiating fremanezumab treatment (index date)
and ≥ 1 month after the index date (i.e., post-index), without
pregnancy or pregnancy-related encounters during the study
period. Patients concomitantly using other CGRP inhibitors
were excluded from the study. The average follow-up duration after fremanezumab initiation for these patients was
12.8 months.
Measures

Data were extracted on patient demographics such as age,
gender, insurance payer, migraine diagnosis, related comorbidities, and ordering physician specialty. Data were also extracted on pre- and post-index patient-reported headache
frequency, migraine pain intensity (MPI), patient-reported
improvement in migraine symptoms, composite migraine
symptoms, and all-cause HCRU (including inpatient hospitalizations, ER, and outpatient visits) and associated cost
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burden (based on billed charges) of each. Manual chart review was used to identify migraine characteristics.
Patient-reported improvement was recorded in the
EMR by physicians and nurses, as a composite binary
variable of “improvement” versus “no improvement” including patient-reported accounts of improvement (i.e.,
yes or no; irrespective of headache frequency) and
patient-reported improvement in headache frequency.
MPI was assessed via responses on a 10-point visual analog scale (VAS) [14] ranging from “no pain” to “worst
pain” (0 = no pain, 10 = worst pain). To be conservative,
the maximum reported headache frequency and intensity values at baseline and follow-up for each patient
were used for the headache frequency and MPI.
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Table 1 Demographics
Characteristic

All patients
(N = 172)

Gender, n (%)
Female

144 (84)

Male

27 (16)

Age in years, mean (SD)

46.0 (12.7)

Mean follow-up in months, mean (SD)

12.8 (4.8)

Fremanezumab dosing, n (%)
Monthly

168 (98)

Quarterly

3 (2)

Ordering physician, n (%)
Neurology

158 (92)

Family medicine

8 (5)

Statistical analysis

Internal medicine

3 (2)

Descriptive statistics were computed to analyze sample
demographics. Nonparametric Wilcoxon signed-rank
tests, with a level of significance set at P < 0.05, were
used to compare means of patient-reported headache
frequency, MPI, and HCRU before and after fremanezumab initiation. To account for the differences in the
follow-up duration for patients, mean HCRU measures
were calculated per month.

Pain medicine

1 (1)

Other

2 (1)

Results
Of the 330 patients with fremanezumab orders in the
database, 127 patients were excluded because they did
not receive administrations of this therapeutic, 26 due to
lack of enrollment or treatment history ≥ 1 month after
the index date, and 5 due to pregnancy diagnosis at any
time during the study period. For the 172 patients who
met all inclusion criteria and constitute the final sample,
the mean (standard deviation [SD]) age was 46.0 (12.7)
years; 84% (144/172) identified as female and 16%
(27/172) as male. Fremanezumab was ordered by neurologists in 92% (158/172) of cases, with family medicine
(5%; 8/172), internal medicine (2%; 3/172), pain medicine (< 1%; 1/172), and other (1%; 2/172) physicians placing the remaining orders. Patient demographics are
displayed in Table 1.
The most common migraine-related comorbid disease
categories during the pre-index period included pain
(37%; 63/172), psychiatric conditions (31%; 53/172),
sleep disturbances (24%; 41/172), and cardiovascular comorbidities (22%; 38/172; Table 2). The most frequent
comorbidities included insomnia (23%; 39/172), anxiety
disorder (including generalized anxiety disorder; 21%;
36/172), chronic pain (21%; 36/172), back pain (19%;
33/172), depression (including major depressive disorder; 19%; 32/172), neck pain (16%; 28/172), and hypertension (16%; 28/172; Table 2).

SD standard deviation

Headache frequency and migraine pain intensity

Pre- and post-index headache frequency data were available
for 76 patients; however, data on 22 of these patients were
excluded from analysis because their self-reported “improvement” was inconsistent with headache frequency reports
(n = 15) or their self-reported “no improvement” was inconsistent with headache frequency reports (n = 7). The 54 patients eligible for headache frequency analysis experienced a
significant decrease in the mean (SD) number of headache
days per month, from 22.24 (9.29) pre-index to 8.24 (7.42)
post-index (P < 0.0001); a mean reduction of 14.00 days
(63%; Table 3, Fig. 1).
Overall, data on improvement in headache frequency
or symptoms were available for 129 patients, of whom
84% (108/129) reported improvement in headache frequency or symptoms after fremanezumab treatment and
16% (21/129) reported no improvement after treatment.
Pre- and post-index MPI was available for 74 patients.
MPI decreased significantly by 18% after fremanezumab
initiation, from a mean (SD) VAS pain score of 5.47
(3.19) pre-index to 4.51 (3.34) post-index (P = 0.014;
Table 3, Fig. 2).
Health care resource utilization

The percentage of patients with any inpatient hospitalizations (12% [20/172] vs. 10% [18/172]), any ER visits
(50% [86/172] vs. 50% [86/172]), and any outpatient
visits (94% [161/172] vs. 94% [162/172]) remained stable
between the pre- and post-index periods. Mean (SD) inpatient hospitalizations per month decreased from 0.21
(0.79) pre-index to 0.16 (0.60) post-index; however, this
decrease was not statistically significant (P = 0.095).
Mean (SD) inpatient hospitalization cost per month also
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Table 2 Patient comorbidities in the pre-index period
Comorbidities, n (%)

All patients
(N = 172)

Psychiatric disorders

53 (31)
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Table 3 Patient-reported improvement, headache frequency,
and migraine pain intensity
P value

Parameter
a

Improvement, n (%)

Depression (including MDD)

32 (19)

Anxiety disorders (including GAD)

36 (21)

Depression and anxiety

19 (11)

Panic disorder

2 (1)

Pre-index, mean (SD)

Bipolar spectrum disorders

8 (5)

Post-index, mean (SD)

Pain

(n = 129)

Yes

108 (84)

No

21 (16)

Headache frequency (overall)

(n = 54)
22.24 (9.29)
8.24 (7.42)

63 (37)

Difference in days, mean

14.00

Fibromyalgia

16 (9)

Difference %, mean

63%

Chronic pain

36 (21)

Back pain

33 (19)

Pre-index, mean (SD)

Neck pain

28 (16)

Post-index, mean (SD)

4.51 (3.34)

Sleep disorders

41 (24)

Difference in days, meanb

0.96

Insomnia

39 (23)

Difference %, mean

18%

Restless leg syndrome

4 (2)

Sleep apnea

18 (10)

Digestive disorders
Irritable bowel syndrome

28 (16)
2 (1)

Constipation

9 (5)

Ulcer

20 (12)

Gastroesophageal reflux disease
Respiratory disorders

19 (11)
29 (17)

Allergies

10 (6)

Sinusitis

11 (6)

Bronchitis

2 (1)

Asthma

17 (10)

Cardiovascular disorders

38 (22)

Hypertension

28 (16)

High cholesterol

15 (9)

Stroke

1 (1)

Mitral valve prolapse

1 (1)

Postural orthostatic tachycardia syndrome

2 (1)

Neurologic disorders
Epilepsy

2 (1)
2 (1)

Endocrine disorder
Diabetes
Hypothyroidism
Metabolic disorders
Obesity

(n = 74)

0.014

SD standard deviation, MPI migraine pain intensity
a
Not reported, n = 43
b
Nonparametric Wilcoxon signed-rank tests, with a level of significance set at
P < 0.05, were used to compare means of patient-reported headache
frequency and MPI before and after fremanezumab initiation

decreased from $2051.91 ($10,003.23) pre-index to
$1359.88 ($6261.16) post-index; similarly, this decrease
was not statistically significant (P = 0.232; Table 4).
Mean (SD) ER visits per month decreased significantly
from 0.72 (1.26) pre-index to 0.54 (0.89) post-index
(P = 0.003); however, the decrease in mean (SD) ER visit
costs per month, from $1300.89 ($4377.38) pre-index to
$1258.30 ($5966.90) post-index, was not statistically significant (P = 0.825; Table 4).
Mean (SD) outpatient visits per month decreased significantly from 1.04 (1.19) pre-index to 0.81 (0.87) postindex (P < 0.001); however, mean (SD) outpatient visit

1 (1)
1 (1)
21 (12)
16 (9)
7 (4)
18 (10)
18 (10)

MDD major depressive disorder, GAD generalized anxiety disorder

< 0.001

5.47 (3.19)

8 (5)

Rheumatoid arthritis

Polycystic ovarian syndrome

MPI (overall)

8 (5)

Autoimmune disorder

Hormonal disorder

b

Fig. 1 Change in headache frequency. SD, standard deviation.
a
P < 0.001 for pre-index vs. post-index
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cost per month increased from $531.21 ($1067.18) preindex to $697.63 ($1665.83) post-index, but the change
was not statistically significant (P = 0.257). An additional
analysis with outpatient cost outliers (i.e., cost
>$5000.00) data excluded yielded a decrease in mean
(SD) outpatient visit cost per month from $465.96
($898.96) pre-index to $459.14 ($823.01) post-index;
however, this change was also not statistically significant
(P = 0.935; Table 4).

Fig. 2 Change in the MPI VAS for headache. MPI, migraine pain intensity;
VAS, visual analog scale; SD, standard deviation. aP = 0.014 for pre-index
vs. post-index

Table 4 Health care resource utilization
HCRU, mean (SD)

All patients (N = 172)

Max

P valuea

Mean hospitalizations (per month)
Pre-index

0.21 (0.79)

6.00

Post-index

0.16 (0.60)

4.38

0.095

Mean hospitalization cost (per month)
Pre-index

$2051.91 (10,003.23)

$93,688.35

Post-index

$1359.88 (6261.61)

$55,951.04

0.232

Mean ER visits (per month)
Pre-index

0.72 (1.26)

7.50

Post-index

0.54 (0.89)

5.36

0.003

Mean ER visit costs (per month)
Pre-index

$1300.89 (4377.38)

$47,351.24

Post-index

$1258.30 (5966.90)

$73,758.67

0.825

Mean outpatient visits (per month)
Pre-index

1.04 (1.19)

7.50

Post-index

0.81 (0.87)

5.36

< 0.001

Mean outpatient visit costs (per month)
Pre-index

$531.21 (1067.18)

$6246.26

Post-index

$697.63 (1665.83)

$14,182.75

0.257

Mean outpatient visit costs (per month) without outliers (i.e., restricting
data to cost ≤$5000.00)
Pre-index

$465.96 (898.96)

$4813.15

Post-index

$459.14 (823.01)

$4477.17

0.935

HCRU health care resource utilization, SD standard deviation,
ER emergency room
a
Nonparametric Wilcoxon signed-rank tests, with a level of significance set at
P < 0.05, were used to compare means of HCRU measures before and after
fremanezumab initiation

Discussion
This retrospective, observational cohort study demonstrated the real-world benefits of fremanezumab as a
preventive treatment for migraine in adults. The results
showed that fremanezumab treatment is associated with
improvements in patient-reported headache frequency,
MPI, and reductions in HCRU and costs. Overall, 84%
of patients with available self-reported data in this study
reported decreases in headache frequency or symptoms
after treatment initiation. Regarding headache frequency,
fremanezumab treatment resulted in a significant 14-day
(−63%) decrease in the patient-reported average number
of headache days per month. The 14-day (or −63%) decrease in the patient-reported average number of headache days per month observed in the present study adds
to the body of evidence suggesting a significant clinical
response to this therapeutic [13, 15, 16]. Of note, despite
the shorter follow-up duration, the reduction in headache frequency observed in this real-world study was
greater than those evidenced in clinical trials (follow-up
duration, 3 to 6 months; −2.6 to −4.6 headache days per
month) [12, 13, 17]. Further, a significant post-treatment
decrease in the patient-reported average MPI of 18%
was also observed. Taken together, these findings further
speak to fremanezumab’s potential to mitigate the significant disability associated with migraine [13], which is
the top cause of years lived with disability among those
15 to 49 years of age [18].
Previous real-world studies have demonstrated that
CGRP pathway–targeted therapies are effective as preventive treatments for migraine in adults [19–22]. In a
Spanish prospective observational study of 155 migraine
patients with ≥ 8 headache days per month and ≥ 3 prior
preventive medication failures, treatment with erenumab
(n = 109) or galcanezumab (n = 46) for 3 months resulted
in a ≥ 50% reduction in migraine days per month in
51.6% of patients (mean [SD] reduction in migraine days
per month compared with baseline was −8.5 [7.7]) [20].
In a sample of 81 Italian patients with high-frequency
EM and CM, treatment with galcanezumab for 3 months
resulted in a significant decrease in monthly migraine
days compared with baseline (EM, −8.5; CM, −11.5; both
P < 0.0001) [21]. A multicenter retrospective chart review of US headache centers evaluated data from
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1034 patients with CM [19]. Results showed that treatment with erenumab for ≥ 3 months resulted in a ≥ 50%
reduction in mean headache/migraine days per month
among 35% of patients. Further, 45% of patients reported improvement in physician-reported migraine severity, and average monthly outpatient visits decreased
from 0.43 at baseline to 0.30 after erenumab initiation.
A separate retrospective real-world analysis that evaluated 6-month follow-up data after ≥ 1 erenumab injection found that, for 43 patients with available data,
monthly migraine days significantly decreased by 8.4
days from baseline [22]. In the current real-world study,
fremanezumab treatment was associated with a 14-day
reduction in the average number of headache days per
month from baseline. Any cross-study comparisons
among these real-world studies should be considered
with caution given the differences in the follow-up periods, outcomes assessed, patient populations, disease severity, and insurance reimbursement policies by region.
Fremanezumab treatment was also associated with significant decreases in HCRU. Compared to pretreatment, statistically significant post-treatment decreases in average ER (25%) and outpatient (22%) visits
were observed. Decreases in average ER and outpatient
visit costs per month were also observed; however, these
changes were not statistically significant. While average
inpatient hospitalizations and average inpatient
hospitalization cost per month also decreased, the results did not reach statistical significance. Mean outpatient costs increased nonsignificantly. This finding was
likely attributable to outliers; an additional analysis excluding outliers (outpatient cost >$5000.00) showed a
decrease in mean outpatient costs, but the results
remained nonstatistically significant. Overall, fremanezumab treatment was associated with reductions in HCRU,
specifically, average ER and outpatient visits; however,
the cost differences across HCRU were not statistically
significant. Reductions in HCRU are pertinent factors in
decision making for policy makers and payers, regarding
reimbursement and medication coverage. For patients,
reducing costs alone may alleviate the financial burden
previously imposed by their disease.
A strength of this observational study is its novel
examination of both clinical outcomes and HCRU and
associated costs simultaneously, compared with most
studies in the literature that evaluated one or the other.
This study design allowed us to examine the association
between improvements in clinical outcomes with fremanezumab treatment and HCRU and cost reductions. Another strength of this study is the methodology used to
collect data. Specifically, the use of the large database
allowed for the analysis of real-world data to demonstrate the benefits of fremanezumab over a longer, more
recent timeframe. Additionally, the database is an
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independent data source, providing impartiality of data
reporting and reducing the likelihood of selection bias.
A limitation of this study was the loss of data from patients with discrepancies between self-reported improvement as a dichotomous “yes/no” measure from their
actual headache frequency reported pre- and postfremanezumab initiation. Although this resulted in data
loss, it ensured validity between the 2 measures of improvement. Furthermore, the results were still statistically significant in an analysis that included all 76
patients with pre- and post-index headache frequency
data. Some patients did not return for follow-up visits
due to improvement in their migraine or other reasons,
and some outcomes were reported by patients via telephone rather than directly in a clinical setting; both may
have increased the potential for misreporting and bias.
Further, this study did not measure or control for the
potential confounding effects of other migraine preventive medications. The loss of data due to the exclusion of
patients or patients who were lost to follow-up may have
limited the potential to detect differences between the
pre- and post-index periods. Further, the loss of data for
patients who did not return for follow-up visits, potentially due to improvement of their migraine, may have
reduced the effect size for post-index outcomes with fremanezumab. These limitations may potentially reduce
the generalizability of these data for the overall population with migraine. Future studies may benefit from first
conducting power analyses to determine the number of
patients necessary in order to detect a significant effect
for improvement.
This study highlights consideration for future studies
aiming to further elucidate fremanezumab’s real-world
effectiveness. Such studies should include a larger, more
diverse sample to increase the generalizability of findings. Given the degree of comorbidities among patients
in this sample, future studies may also use patients’
treatment history and associated diagnostic codes to
control for the confounding effects of other medications
(migraine or otherwise) and non–migraine-related encounters. Such factors may explain why outpatient visit
costs were observed to increase in this study for some
patients, while all other costs decreased. Finally, in
addition to continuing to evaluate the safety and effectiveness of this therapeutic as a preventive treatment for
migraine, future studies may include pre- and postmeasures of days of work, productivity, and/or income
to further assess the improvements in migraine-related
disability associated with fremanezumab treatment.

Conclusion
Fremanezumab treatment was associated with significant
reductions in headache frequency, MPI, and HCRU,
which may also improve quality of life for patients with
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migraine. Less HCRU translated to substantial reductions in hospitalization and ER costs. Fremanezumab
treatment was also associated with patient-reported improvements in migraine-associated symptoms, which
may be even more pervasive and burdensome than the
headaches themselves. The data from this study may aid
clinical decision making for patients with migraine and
the development of coverage and utilization management policy.
Abbreviations
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